Literature DB >> 30740317

The transition of pediatric Marfan patients to adult care: a challenge and its risks.

Veronika C Stark1, Katrin Doering1, Yskert von Kodolitsch2, Rainer Kozlik-Feldmann1, Götz C Mueller1, Jakob Olfe1, Meike Rybczynski2, Helke Schueler2, Thomas S Mir1.   

Abstract

BACKGROUND: Care for patients with Marfan syndrome (MFS) has improved substantially in recent decades. Increasing clinical knowledge and genetic analysis allow early diagnosis of the disease in childhood. Because of the earlier initiation to preventive and medical treatment, patients' life expectancy has risen. To ensure optimal care, pediatric patients require a safe follow-up regime, multidisciplinary care, and a safe transition to adult care.
METHODS: We collected a sample of 149 pediatric Marfan patients, of whom 34 patients had already been transferred to adult care or who were currently transitioning. First, we evaluated clinical aspects of patients that manifest in childhood and are present in the transition process. Second, we analyzed the transition process itself.
RESULTS: We found age-dependent manifestation of organ pathologies. Dilatation of the sinus of Valsalva showed a particularly high prevalence during the transition process and 62% of patients required medical treatment. Mean onset of aortic root dilatation was 9.9±5.8 years. Concerning systemic manifestation in MFS skin striae, wrist and thumb sign, and reduced elbow extension occurred significantly more often in patients who were transitioning than in younger children with MFS. All other clinical Marfan features showed an increased prevalence in patients who were transitioning compared with younger patients. In our cohort, transition was successful in 20 patients (58.9%), 12 patients (35.3%) are still in the transition process and 2 patients (5.9%) were lost to follow up.
CONCLUSIONS: Marfan patients in the transition process are already under a chronic disease condition with a high onset of especially cardiovascular pathologies. Although early medical treatment in childhood is effective, the pathologies of the connective tissue require lifelong attention and influence life in many ways. The big challenge during transition is the double change of responsibility from the parents and pediatric doctor to the patient and adult doctor. Consequently, patients in transition process require special attention and close contact with the doctor and the family. A reevaluation by the supervising pediatric Marfan specialist of the successful transition to adult care is indispensable before the pediatric care of Marfan patients is completed.

Entities:  

Keywords:  Aortic dilatation; Marfan syndrome (MFS); medical treatment; systemic manifestation; transition process

Year:  2018        PMID: 30740317      PMCID: PMC6331371          DOI: 10.21037/cdt.2018.09.13

Source DB:  PubMed          Journal:  Cardiovasc Diagn Ther        ISSN: 2223-3652


  24 in total

Review 1.  Treatment of aortic disease in patients with Marfan syndrome.

Authors:  Dianna M Milewicz; Harry C Dietz; D Craig Miller
Journal:  Circulation       Date:  2005-03-22       Impact factor: 29.690

2.  Living with Marfan syndrome: coping with stigma.

Authors:  Kf Peters; Ka Apse; A Blackford; B McHugh; D Michalic; Bb Biesecker
Journal:  Clin Genet       Date:  2005-07       Impact factor: 4.438

Review 3.  Marfan's syndrome.

Authors:  Daniel P Judge; Harry C Dietz
Journal:  Lancet       Date:  2005-12-03       Impact factor: 79.321

Review 4.  Marfan syndrome: an update of genetics, medical and surgical management.

Authors:  Yskert von Kodolitsch; Peter N Robinson
Journal:  Heart       Date:  2007-06       Impact factor: 5.994

5.  Marfan syndrome: 30 years of research equals 30 years of additional life expectancy.

Authors:  Reed E Pyeritz
Journal:  Heart       Date:  2008-11-10       Impact factor: 5.994

Review 6.  Medical management of Marfan syndrome.

Authors:  Martin G Keane; Reed E Pyeritz
Journal:  Circulation       Date:  2008-05-27       Impact factor: 29.690

7.  The revised Ghent nosology for the Marfan syndrome.

Authors:  Bart L Loeys; Harry C Dietz; Alan C Braverman; Bert L Callewaert; Julie De Backer; Richard B Devereux; Yvonne Hilhorst-Hofstee; Guillaume Jondeau; Laurence Faivre; Dianna M Milewicz; Reed E Pyeritz; Paul D Sponseller; Paul Wordsworth; Anne M De Paepe
Journal:  J Med Genet       Date:  2010-07       Impact factor: 6.318

8.  Pediatric self-management: a framework for research, practice, and policy.

Authors:  Avani C Modi; Ahna L Pai; Kevin A Hommel; Korey K Hood; Sandra Cortina; Marisa E Hilliard; Shanna M Guilfoyle; Wendy N Gray; Dennis Drotar
Journal:  Pediatrics       Date:  2012-01-04       Impact factor: 7.124

Review 9.  Marfan syndrome-diagnosis and management.

Authors:  Naser M Ammash; Thoralf M Sundt; Heidi M Connolly
Journal:  Curr Probl Cardiol       Date:  2008-01       Impact factor: 5.200

10.  Health-related quality of life in Marfan syndrome: a cross-sectional study of Short Form 36 in 84 adults with a verified diagnosis.

Authors:  Svend Rand-Hendriksen; Heidi Johansen; Svein Ove Semb; Odd Geiran; Johan K Stanghelle; Arnstein Finset
Journal:  Genet Med       Date:  2010-08       Impact factor: 8.822

View more
  2 in total

Review 1.  Marfan syndrome.

Authors:  Dianna M Milewicz; Alan C Braverman; Julie De Backer; Shaine A Morris; Catherine Boileau; Irene H Maumenee; Guillaume Jondeau; Arturo Evangelista; Reed E Pyeritz
Journal:  Nat Rev Dis Primers       Date:  2021-09-02       Impact factor: 65.038

Review 2.  A scoping review presenting a wide variety of research on paediatric and adolescent patients with Marfan syndrome.

Authors:  Ingeborg Beate Lidal; Trine Bathen; Heidi Johansen; Gry Velvin
Journal:  Acta Paediatr       Date:  2020-02-17       Impact factor: 2.299

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.